Literature DB >> 12719389

Long term outcome of neonatal meningitis.

J P Stevens1, M Eames, A Kent, S Halket, D Holt, D Harvey.   

Abstract

OBJECTIVES: To quantify long term impairment after neonatal meningitis.
DESIGN: Longitudinal case-control study over 9-10 years. SUBJECTS AND METHODS: A total of 111 children who had suffered neonatal meningitis were seen and compared with 113 matched controls from their birth hospital and 49 controls from general practices. Assessments included the WISC III(UK), movement assessment battery for children (mABC), audiometry, vision testing, and social and medical data. Statistical analysis was by multiple regression, analysis of variance, and chi(2) tests.
RESULTS: Some 10.8% of cases had a severe and 9% a moderate overall outcome compared with 0% and 1.8% for the hospital controls. The mean intelligence quotient (IQ) of the cases (88.8) was significantly less than that of the hospital controls (99.4) or the GP controls (99.6). The mABC score was significantly worse for the cases (7.08) than the hospital (5) or GP (4) controls. Some 3.6% of cases had sensorineural hearing loss, 2.7% had persisting hydrocephalus; no controls did. Some 5.4% of cases and 1.7% of hospital controls had treatment for seizures.
CONCLUSIONS: Severe neurodisability and milder motor and psychometric impairment result from neonatal meningitis. Both clinical follow up and comprehensive developmental assessment are needed after this disease.

Entities:  

Mesh:

Year:  2003        PMID: 12719389      PMCID: PMC1721546          DOI: 10.1136/fn.88.3.f179

Source DB:  PubMed          Journal:  Arch Dis Child Fetal Neonatal Ed        ISSN: 1359-2998            Impact factor:   5.747


  18 in total

1.  Infantile meningitis in England and Wales: a two year study.

Authors:  J de Louvois; J Blackbourn; R Hurley; D Harvey
Journal:  Arch Dis Child       Date:  1991-05       Impact factor: 3.791

2.  The sequelae of group B beta-hemolytic streptococcal meningitis in early infancy.

Authors:  R H Haslam; J R Allen; M M Dorsen; D L Kanofsky; E D Mellitus; D A Norris
Journal:  Am J Dis Child       Date:  1977-08

3.  Long-term sequelae of neonatal meningitis.

Authors:  P M Fitzhardinge; M Kazemi; M Ramsay; L Stern
Journal:  Dev Med Child Neurol       Date:  1974-02       Impact factor: 5.449

4.  The maturation of linear acuity and compliance with the Sonksen-Silver Acuity System in young children.

Authors:  A T Salt; P M Sonksen; A Wade; R Jayatunga
Journal:  Dev Med Child Neurol       Date:  1995-06       Impact factor: 5.449

5.  Sequelae of early-onset group B hemolytic streptococcal neonatal meningitis.

Authors:  K C Chin; P M Fitzhardinge
Journal:  J Pediatr       Date:  1985-05       Impact factor: 4.406

6.  Long-term outcome of neonatal meningitis.

Authors:  S M Franco; V E Cornelius; B F Andrews
Journal:  Am J Dis Child       Date:  1992-05

7.  Coordination of low birthweight seven-year-olds.

Authors:  A M Elliman; E M Bryan; A D Elliman; J Walker; D R Harvey
Journal:  Acta Paediatr Scand       Date:  1991-03

8.  Cognitive, educational, and behavioural outcomes at 7 to 8 years in a national very low birthweight cohort.

Authors:  L J Horwood; N Mogridge; B A Darlow
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  1998-07       Impact factor: 5.747

9.  Long-term outcome of group B streptococcal meningitis.

Authors:  E R Wald; I Bergman; H G Taylor; D Chiponis; C Porter; K Kubek
Journal:  Pediatrics       Date:  1986-02       Impact factor: 7.124

10.  Prospective surveillance of neonatal meningitis.

Authors:  L Hristeva; R Booy; I Bowler; A R Wilkinson
Journal:  Arch Dis Child       Date:  1993-07       Impact factor: 3.791

View more
  32 in total

1.  Extracellular loops of the Eschericia coli outer membrane protein A contribute to the pathogenesis of meningitis.

Authors:  Ravi Maruvada; Kwang Sik Kim
Journal:  J Infect Dis       Date:  2011-01-01       Impact factor: 5.226

2.  Rapid diagnosis of bacterial meningitis by real-time PCR and fluorescence in situ hybridization.

Authors:  Sven Poppert; Andreas Essig; Barbara Stoehr; Adelinde Steingruber; Beate Wirths; Stefan Juretschko; Udo Reischl; Nele Wellinghausen
Journal:  J Clin Microbiol       Date:  2005-07       Impact factor: 5.948

3.  Long-term health and socioeconomic consequences of childhood and adolescent onset of meningococcal meningitis.

Authors:  Line Pickering; Poul Jennum; Rikke Ibsen; Jakob Kjellberg
Journal:  Eur J Pediatr       Date:  2018-06-20       Impact factor: 3.183

4.  Host cytosolic phospholipase A₂α contributes to group B Streptococcus penetration of the blood-brain barrier.

Authors:  Ravi Maruvada; Longkun Zhu; Donna Pearce; Adam Sapirstein; Kwang Sik Kim
Journal:  Infect Immun       Date:  2011-08-08       Impact factor: 3.441

5.  IbeA and OmpA of Escherichia coli K1 exploit Rac1 activation for invasion of human brain microvascular endothelial cells.

Authors:  Ravi Maruvada; Kwang Sik Kim
Journal:  Infect Immun       Date:  2012-03-26       Impact factor: 3.441

Review 6.  Mechanisms of microbial traversal of the blood-brain barrier.

Authors:  Kwang Sik Kim
Journal:  Nat Rev Microbiol       Date:  2008-07-07       Impact factor: 60.633

Review 7.  Human Meningitis-Associated Escherichia coli.

Authors:  Kwang Sik Kim
Journal:  EcoSal Plus       Date:  2016-05

8.  Cerebrospinal fluid reference ranges in term and preterm infants in the neonatal intensive care unit.

Authors:  Lakshmi Srinivasan; Samir S Shah; Michael A Padula; Soraya Abbasi; Karin L McGowan; Mary C Harris
Journal:  J Pediatr       Date:  2012-05-09       Impact factor: 4.406

Review 9.  A maternal vaccine against group B Streptococcus: past, present, and future.

Authors:  Vincent L Chen; Fikri Y Avci; Dennis L Kasper
Journal:  Vaccine       Date:  2013-08-28       Impact factor: 3.641

10.  Evaluation of the BioFire FilmArray meningitis/encephalitis panel for the detection of bacteria and yeast in Chinese children.

Authors:  Bailu Du; Chunzhen Hua; Yijun Xia; Jin Li; Yongping Xie; Yue Tao; Qing Cao; Xi Mo
Journal:  Ann Transl Med       Date:  2019-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.